Efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus: a Meta-analysis

周泓羽; 杜渝平; 袁喆

您当前的位置：

首页 >

文章列表页 >

Efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus: a Meta-analysis

更新时间：2026-01-09

- Efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus: a Meta-analysis
- Journal of Army Medical University Vol. 35, Issue 20, Pages: 2220-2225(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R181.23;R512.62;R978.7
- Published：2013
- 稿件说明：
移动端阅览
周泓羽,杜渝平,袁喆.替比夫定对乙型肝炎病毒母婴阻断效果的Meta分析[J].陆军军医大学学报(原第三军医大学学报),2013,35(20):2220-2225.

　Zhou Hongyu,Du Yuping,Yuan Zhe.Efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus: a Meta-analysis[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(20):2220-2225.
周泓羽,杜渝平,袁喆.替比夫定对乙型肝炎病毒母婴阻断效果的Meta分析[J].陆军军医大学学报(原第三军医大学学报),2013,35(20):2220-2225. DOI：

　Zhou Hongyu,Du Yuping,Yuan Zhe.Efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus: a Meta-analysis[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(20):2220-2225. DOI：

摘要

目的综合评价替比夫定阻断乙型肝炎病毒母婴传播的效果。方法检索国内外有关替比夫定阻断HBV母婴传播的临床对照试验文献，通过Meta分析方法，对HBV感染孕妇的HBV DNA定量水平及婴儿HBsAg、HBV DNA血清学阳性率进行合并分析。结果替比夫定组孕妇HBV DNA水平较治疗前下降（WMD=3.62，95%CI=3.41~3.82，

0.01），且分娩前HBV DNA水平低于对照组（WMD=-3.51，95%CI=-3.79~-3.23，

0.01）。婴儿出生后24 h内，替比夫定组的HBsAg阳性率、HBV DNA阳性率分别为11.5%、3.9%，低于对照组的25.8%、17.7%（RR=0.45，95%CI=0.32~0.63，

0.01；RR=0.26，95%CI=0.15~0.44，

0.01）。婴儿6月龄，替比夫定组的HBV DNA阳性率为2.6%，低于对照组的19.2%（RR=0.15，95%CI=0.06~0.39，

0.01）。婴儿12月龄，替比夫定组的HBsAg阳性率、HBV DNA阳性率分别为3.8%、2.2%，低于对照组的21.5%、16.6%（RR=0.18，95%CI=0.09~0.39，

0.01；RR=0.15，95%CI=0.06~0.38，

0.01）。结论在孕中后期使用替比夫定进行抗病毒治疗，能够降低孕妇乙肝病毒载量，最终起到较好的乙型肝炎病毒母婴阻断效果。

Abstract

Objective To evaluate the efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus (HBV)

and to provide a basis for the prevention and control of mother-to-child transmission of HBV. Methods We retrieved the domestic and foreign literatures about controlled clinical trials of telbivudine preventing mother-to-child transmission of HBV. Meta-a

nalysis was used to analyze HBV DNA level of HBV-infected pregnant women

and HBsAg and HBV DNA seropositivity of infants. Results The HBV DNA level of pregnant women of telbivudine group was decreased after treatment (WMD=3.62

95%CI=3.41 to 3.82

0.01)

and was lower than those in control group before parturition (WMD=-3.51

95%CI=-3.79 to -3.23

0.01). Within 24 hours after infants birth

the seropositivity of HBsAg and HBV DNA of telbivudine group infants were 11.5% and 3.9% respectively

lower than those in control group

25.8% and 17.7% respectively (RR=0.45

95%CI=0.32 to 0.63

0.01; RR=0.26

95%CI=0.15 to 0.44

0.01). The HBV DNA seropositivity of 6-month infants from telbivudine group was 2.6%

lower than 19.2% for the control group (RR=0.15

95%CI=0.06 to 0.39

0.01). The seropositivity of HBsAg and HBV DNA of 12-month infants from telbivudine group were 3.8% and 2.2% respectively

lower than 21.5% and 16.6% for the control group (RR=0.18

95%CI=0.09 to 0.39

0.01; RR=0.15

95%CI=0.06 to 0.38

0.01). Conclusion Telbivudine treatment during the second and third trimester of pregnancy reduces HBV DNA level in pregnant women

and ultimately prevents mother-to-child transmission of HBV.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Meta-analysis of probiotics in adjuvant treatment of Parkinson’s disease

Dynamic analysis of serum markers of HBV in 302 infants of pregnant women with HBV infection

Establishment and efficacy observation of a surgical model for controlling abdominal explosive wound in pigs

Effects of telbivudine on transmission of HBsAg and HBeAg through placenta in HBV infected pregnant women in second or third trimester

Related Author

陈阳美

范文辉

张靖萍

雷玉铃

沈法

刘慧敏

王静

朱研

Related Institution

No data

⁰